PMID- 32175766
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 2042-6313 (Electronic)
IS  - 2042-6305 (Linking)
VI  - 9
IP  - 7
DP  - 2020 May
TI  - Real-world evidence on clinical outcomes in immune thrombocytopenia treated with 
      thrombopoietin receptor agonists.
PG  - 447-457
LID - 10.2217/cer-2019-0177 [doi]
AB  - Aim: Eltrombopag and romiplostim are US FDA approved for treatment of immune 
      thrombocytopenia in patients with insufficient response to other treatments. 
      Clinical or real-world data comparing outcomes of the two drugs are limited. 
      Methods: This retrospective cross-sectional study sought information on 
      bleeding-related episodes (BREs), adverse events (AEs) and other outcomes of 
      eltrombopag or romiplostim treatment in immune thrombocytopenia. Results: 
      Patients receiving eltrombopag experienced significantly reduced BREs, severe 
      BREs, rescue medication use and platelet transfusions. Diarrhea and headache were 
      significantly less frequent in patients receiving eltrombopag; other AEs occurred 
      equally in both groups. Conclusion: There may be a potential advantage for the 
      use of eltrombopag versus romiplostim in the practice settings studied, based on 
      rates of BREs and AEs and rescue medication utilization.
FAU - Forsythe, Anna
AU  - Forsythe A
AD  - Evidence Generation, Purple Squirrel Economics, New York, NY 10010, USA.
FAU - Schneider, John
AU  - Schneider J
AD  - Avalon Health Economics, Morristown, NJ 07960, USA.
FAU - Pham, Timothy
AU  - Pham T
AD  - Health Economics and Outcomes Research, Novartis, East Hanover, NJ 07936, USA.
FAU - Bhor, Menaka
AU  - Bhor M
AD  - Health Economics and Outcomes Research, Novartis, East Hanover, NJ 07936, USA.
FAU - Said, Qayyim
AU  - Said Q
AD  - Health Economics and Outcomes Research, Novartis, East Hanover, NJ 07936, USA.
FAU - Allepuz, Alejandro
AU  - Allepuz A
AD  - Clinical Development, Novartis Pharma AG, Basel, Switzerland.
FAU - Socorro O Portella, Maria do
AU  - Socorro O Portella MD
AD  - Oncology Clinical Development, Novartis, East Hanover, NJ 07936, USA.
FAU - Kwon, Christina S
AU  - Kwon CS
AD  - Evidence Generation, Purple Squirrel Economics, New York, NY 10010, USA.
FAU - Roy, Anuja Nidumolu
AU  - Roy AN
AD  - Health Economics and Outcomes Research, Novartis, East Hanover, NJ 07936, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200316
PL  - England
TA  - J Comp Eff Res
JT  - Journal of comparative effectiveness research
JID - 101577308
RN  - 0 (Benzoates)
RN  - 0 (Hydrazines)
RN  - 0 (Pyrazoles)
RN  - 0 (Receptors, Fc)
RN  - 0 (Receptors, Thrombopoietin)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9014-42-0 (Thrombopoietin)
RN  - GN5XU2DXKV (romiplostim)
RN  - S56D65XJ9G (eltrombopag)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Benzoates/adverse effects/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Hydrazines/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Platelet Count
MH  - Purpura, Thrombocytopenic, Idiopathic/*drug therapy
MH  - Pyrazoles/adverse effects/*therapeutic use
MH  - Receptors, Fc/*therapeutic use
MH  - Receptors, Thrombopoietin/*agonists
MH  - Recombinant Fusion Proteins/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Thrombopoietin/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - adverse events
OT  - bleeding episodes
OT  - eltrombopag
OT  - immune thrombocytopenia
OT  - romiplostim
OT  - treatment outcomes
EDAT- 2020/03/17 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/03/17 06:00
PHST- 2020/03/17 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2020/03/17 06:00 [entrez]
AID - 10.2217/cer-2019-0177 [doi]
PST - ppublish
SO  - J Comp Eff Res. 2020 May;9(7):447-457. doi: 10.2217/cer-2019-0177. Epub 2020 Mar 
      16.